Why the study?
What are the pharmacokinetic differences in the metabolism of procainamide between normal subjects and patients with heart disease?
Population
10 subjects (5 normal subjects and 5 patients with heart disease)
Comparison
Procainamide 500 to 1,000 mg orally, along with… vs Normal subjects compared to patients with heart…
Design
Cohort
Follow-up
72 hours
Authors
Loading...
May warrant procainamide dose caution in cardiac patients; extends healthy-volunteer PK data but leaves open prospective validation.
What are the pharmacokinetic differences in the metabolism of procainamide between normal subjects and patients with heart disease?
Patients with heart disease exhibit delayed elimination and higher peak plasma concentrations of procainamide and its active metabolite NAPA compared to healthy subjects, suggesting a need for dose adjustments.
Giardina et al. (1976) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: